Amgen is scheduled to report its third-quarter financial results after the markets close on Wednesday.
Amgen is slowly getting closer to an FDA final decision for its first-of-a-kind cancer therapy, talimogene laherparepvec (T-Vec).
Source: ThinkstockCancer ranks on the list of global killers as number two. Over the years, great strides have been made not only in cancer treatment but in survival rates for many different forms...